Abstract | AIM: To evaluate the effect of statins on reducing new-onset atrial fibrillation (AF) in a large real-world post- myocardial infarction (MI) population. Subsequently, to test if different statin doses, various types and compliance affected the incidence of new-onset AF post MI. METHODS: All patients with first-time acute MI between 1997 and 2009 in Denmark and claimed prescriptions of statins after discharge were identified from the Danish nationwide administrative registers. Patients with a history of AF were excluded. Risk of new-onset AF according to statin use were analysed by multivariable time-dependent Cox regressions models adjusted for age, gender, year, concomitant medication, and comorbidity, and additionally in a propensity score-matched analysis. RESULTS: A total of 89,703 patients with average follow up of 5.0 ± 3.5 years were included in this study. In the 56,044 patients receiving statins, 5698 (10%) had new-onset AF vs. 5010 (15%) in the 33,659 patients serving as controls. The adjusted Cox regression analysis showed significant reduction in new-onset AF (HR 0.83, 95% CI 0.80-0.87, p < 0.001) in statin users. Adjustment for propensity score yielded nearly identical results (HR 0.82, 95% CI 0.78-0.85, p < 0.001). Furthermore, patients compliant to statin treatment had significant reduction in new-onset AF (HR 0.84, 95% CI 0.80-0.87, p < 0.001). Finally, simvastatin and atorvastatin were significantly more effective than pravastatin (both p < 0.01) in reducing new-onset AF. CONCLUSIONS:
Statin therapy was significantly associated with less new-onset AF in a nationwide cohort of post-MI patients. Furthermore, statins showed a type-dependent effect in preventing new-onset AF. These results support the beneficial effect of statin therapy beyond lipid lowering in patients with MI and underline the importance of statin adherence and choice of statin type.
|
Authors | Casper N Bang, Gunnar H Gislason, Anders M Greve, Christian Torp-Pedersen, Lars Køber, Kristian Wachtell |
Journal | European journal of preventive cardiology
(Eur J Prev Cardiol)
Vol. 21
Issue 3
Pg. 330-8
(Mar 2014)
ISSN: 2047-4881 [Electronic] England |
PMID | 23012689
(Publication Type: Comparative Study, Journal Article, Observational Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Heptanoic Acids
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Pyrroles
- Atorvastatin
- Simvastatin
- Pravastatin
|
Topics |
- Age Factors
- Aged
- Aged, 80 and over
- Atorvastatin
- Atrial Fibrillation
(diagnosis, epidemiology, prevention & control)
- Chi-Square Distribution
- Comorbidity
- Denmark
(epidemiology)
- Female
- Heptanoic Acids
(therapeutic use)
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(therapeutic use)
- Male
- Medication Adherence
- Middle Aged
- Multivariate Analysis
- Myocardial Infarction
(diagnosis, epidemiology, therapy)
- Polypharmacy
- Pravastatin
(therapeutic use)
- Propensity Score
- Proportional Hazards Models
- Pyrroles
(therapeutic use)
- Registries
- Retrospective Studies
- Risk Factors
- Sex Factors
- Simvastatin
(therapeutic use)
- Time Factors
- Treatment Outcome
|